Highlights•Oncogenic drivers and mechanisms of adaptive immunity are changing the
landscape of lung cancer treatment.•Cancers can disrupt cancer cell immune recognition by …

Purpose d-limonene is a plant extract with widespread application, and it has been recently
reported to have antiproliferative and proapoptotic effects on cancer cells. However, the …

Aim: Little is known about recent treatment patterns among patients with unresected stage III
NSCLC in the real world. This retrospective study used medical records from USA …

Drug resistance is an obstacle in the chemotherapeutic treatment of lung cancers. In the
present study, the effects of high-mobility group box 1 (HMGB1) protein in chemotherapeutic …

Lung cancer has been a hot area of research because of its high incidence and mortality. In
this study, WWP2, an E3 ubiquitin ligase, is proposed to be an oncoprotein contributing to …

Purpose The objective of this randomised phase II study was to evaluate the impact in terms
of response and toxicities of induction or consolidation chemotherapy respectively before or …

Lung cancer is the deadliest type of cancer for both men and women. In this study, we
evaluate the in vitro and in vivo efficacy of a biotherapeutic agent composed of a lysosomal …

Die aktuelle Fassung der Leitlinie Lungenkarzinom trägt der Dynamik der Informationen in
diesem Fachbereich Rechnung. Insbesondere gelten folgenden Empfehlungen: Die …

Expression of the EGF receptors (EGFRs) is abnormally high in many types of cancer,
including 25% of lung cancers. Successful treatments target mutations in the EGFR tyrosine …

New advances in the treatment of non–small cell lung cancer (NSCLC) have afforded
patients longer progression-free survival times, but these therapies are also associated with …